ClinicalTrials.gg
RecruitingNCT03728166DC-eALERTUpdated Sep 29, 2026

Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)

An interventional study of Electronic alert in Venous Thromboembolism, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Feb 2019; still recruiting 7 years 9 months later.
Updated Sep 29, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Venous Thromboembolism by Brigham and Women's Hospital — 2 open to participants now, 2 under way, none of them phase 3. Venous Thromboembolism · Brigham and Women's Hospital.

Started
2019
with 1 other
No phase
4 of 13
1 open now
Registered
6th of 13
by date

Among the 13 studies in Venous Thromboembolism by Brigham and Women's Hospital, this one is one of 2 that started in 2019, is one of 4 with no phase, and was the 6th registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

2 of the 13 studies in Venous Thromboembolism by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Venous Thromboembolism by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge. In the APEX Trial of hospitalized patients with acute medical illness, extended-duration post-discharge thromboprophylaxis with oral betrixaban reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death compared with short-duration enoxaparin. Obstacles to integration of these data in the hospitalized Medical Service patient population, including failure to identify at-risk patients, educational gaps in strategies for VTE prevention after discharge, and medication nonadherence, can be overcome with alert-based computerized decision support. This study is a single-center, 400-patient, randomized controlled trial of an EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase prescription of extended-duration post-discharge thromboprophylaxis and decrease symptomatic VTE in high-risk patients hospitalized with medical illness.

Specific Aim #1: To determine the impact of electronic alert-based CDS (EPIC Best Practice Advisory [BPA]) on prescription of extended-duration post-discharge thromboprophylaxis in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.

Specific Aim #2: To estimate the impact of electronic alert-based CDS (EPIC BPA) on the frequency of symptomatic VTE in high-risk patients hospitalized with medical illness who are not being prescribed any prophylactic anticoagulation for VTE prevention after discharge.

Read the detailed description

Design: U.S.-based, single-center, randomized controlled trial

Background: Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care (from before admission to after discharge). In the APEX Trial of 7513 hospitalized patients with acute medical illness, reduced mobility, and risk factors for VTE, extended-duration post-discharge thromboprophylaxis with oral betrixaban for 35 to 42 days reduced the frequency of asymptomatic proximal deep venous thrombosis (DVT), symptomatic proximal or distal DVT, symptomatic nonfatal pulmonary embolism (PE), or VTE-related death by 24% in the overall study population compared with 10-14 days of enoxaparin. The integration of oral betrixaban with a computerized decision support (CDS) tool has the potential to increase the appropriate prescription of extended-duration post-discharge thromboprophylaxis in high-risk patients hospitalized with medical illness.

Study Design: 400-patient U.S.-based single-center Quality Improvement Initiative in the form of a randomized controlled trial focused on the feasibility of implementation of this electronic alert-based CDS (EPIC BPA) (Figure 1). The allocation ratio will be 1:1 for an electronic alert-based CDS (EPIC BPA) notification versus no notification.

Study Population: Patients are eligible if they are ≥40 years of age, are hospitalized for acute medical illness (heart failure, respiratory failure, infectious disease, rheumatic disease, or ischemic stroke), have reduced mobility, and have one additional risk factor for VTE:

  1. Age ≥60
  2. Prior VTE
  3. History of cancer

Eligible patients are not prescribed thromboprophylaxis at hospital discharge.

Intervention: An EPIC Electronic Health Record (EHR) Best Practice Advisory (BPA) will identify patients hospitalized with medical illness who are not ordered for extended-duration, post-discharge thromboprophylaxis 48 hours after admission. A first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. A second on-screen electronic alert will be issued if extended-duration, post-discharge thromboprophylaxis has still not been ordered that again notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis.

Primary Efficacy Outcome: Prescription of extended-duration post-discharge thromboprophylaxis. Investigators will review the order entry section of the Electronic Health Record (EPIC) to make this determination.

Secondary Efficacy Outcome: Frequency of symptomatic VTE at 90 days from randomization. Investigators will review the notes and diagnostic testing sections of the Electronic Health Record (EPIC) to make this determination. The proposed study will not be powered to show a difference in clinical events, such as symptomatic VTE, with the electronic alert-based CDS but will provide estimates from which to plan a possible subsequent multi-center trial.

Primary Safety Outcome: Major bleeding (as defined by the ISTH bleeding classification system) at 90 days from randomization. Investigators will review the notes and diagnostic testing sections of the Electronic Health Record (EPIC) to make this determination. The proposed study will not be powered to show a difference in clinical events, such as bleeding, with the electronic alert-based CDS but will provide estimates from which to plan a possible subsequent multi-center trial.

Follow-Up: Follow-up will consist of Electronic Health Record review at 90 days from randomization.

03

Conditions studied

  • Venous Thromboembolism

Keywords

  • venous thromboembolism
  • prevention
  • medical patients
  • hospital discharge
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-≥40 years of age, are hospitalized for acute medical illness (heart failure, respiratory failure, infectious disease, rheumatic disease, or ischemic stroke), have reduced mobility, are not prescribed thromboprophylaxis at hospital discharge, and have one additional risk factor for VTE:

  • Age ≥60
  • Prior VTE OR
  • History of cancer

Exclusion criteria

Exclusion Criteria:

- Prescribed thromboprophylaxis at hospital discharge

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Alert

    On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a "Extended-Duration VTE Prevention" order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis.

    Behavioral: Electronic alert

  • No intervention
    No Alert

    No notification to the provider.

Interventions

  • BehavioralElectronic alert

    On-screen electronic alert that notifies the provider about the increased risk for VTE after discharge and indication for thromboprophylaxis will be issued 48 hours after admission. This first on-screen electronic alert will provide the clinician with the opportunity to consider extended-duration, post-discharge thromboprophylaxis and start any required processes for prior authorization or medication coverage. The provider then will be given on-screen options to either order thromboprophylaxis (betrixaban or low-molecular weight heparin for 35 days) from a "Extended-Duration VTE Prevention" order template, follow a link to evidence-based practice guidelines, or defer prescribing extended-duration, post-discharge thromboprophylaxis.

06

What researchers measure

Primary outcomes

  1. Frequency of prescription of extended-duration post-discharge thromboprophylaxis.

    Investigators will review the order entry section of the Electronic Health Record (EPIC) to make this determination.

    Time frame: 90 days

Secondary outcomes

  1. Frequency of symptomatic VTE at 90 days from randomization.

    Investigators will review the notes and diagnostic testing sections of the Electronic Health Record (EPIC) to make this determination. The proposed study will not be powered to show a difference in clinical events, such as symptomatic VTE, with the electronic alert-based CDS but will provide estimates from which to plan a possible subsequent multi-center trial.

    Time frame: 90 days

  2. Frequency of major bleeding (as defined by the ISTH bleeding classification system) at 90 days from randomization.

    Investigators will review the notes and diagnostic testing sections of the Electronic Health Record (EPIC) to make this determination. The proposed study will not be powered to show a difference in clinical events, such as bleeding, with the electronic alert-based CDS but will provide estimates from which to plan a possible subsequent multi-center trial.

    Time frame: 90 days

  3. Frequency of all-cause mortality at 90 days

    Any death confirmed by medical record

    Time frame: 90 days

  4. Frequency of all-cause rehospitalization at 90 days

    Any rehospitalization confirmed by medical record

    Time frame: 90 days

Other outcomes

  1. Medication adherence

    The proportion of patients who completed the 35-day course of post-discharge thromboprophylaxis.

    Time frame: 35 days

07

Study locations

1 of 1 sites recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
    • Gregory Piazza, MD · Contactgpiazza@partners.org · 857-307-1932
    • Gregory Piazza, MD · Principal investigator
    • Samuel Z Goldhaber, MD · Principal investigator
08

References and documents

Publications

  • Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747. Epub 2016 May 27. PubMed 27232649 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Dec 2022, 46 months.

Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's 46 months is above that.

Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2018
First posted
Nov 1, 2018
StartActual
Feb 1, 2019
Primary completionActual
Dec 31, 2022
CompletionEst.
Dec 30, 2026was Jun 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jun 30, 2026→Dec 30, 2026
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Study completion Jun 30, 2026→Dec 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03728166
Responsible party
Gregory Piazza, MD, MS (Associate Director, Thrombosis Research Group, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 1, 2018
Start date
Feb 1, 2019
Primary completion
Dec 31, 2022
Completion
Dec 30, 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

Gregory Piazza, MD, MS
Contact
gpiazza@bwh.harvard.edu
6177326984
Claire E Galvin, BS
Contact
cegalvin@bwh.harvard.edu
6177326984
Gregory Piazza, MD, MS
principal investigator · BWH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion